POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to tame bone marrow cancer
Disease control Recruiting nowThis early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Massive new study aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC